---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022227"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2026-05-11T20:10:43+00:00"
generated_at: "2026-05-11T22:19:08.053982+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%

## Summary
- Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.
- Net loss of $27.6M ($0.74 diluted EPS) vs. loss of $17.8M ($0.50) in Q1 2025; Adjusted EBITDA -$12.7M.
- VEVYE delivered record quarterly prescriptions: NRx +25% QoQ, TRx +11% QoQ; surpassed XIIDRA on monthly TRx with ~14% market share.
- IHEEZO unit demand +18% YoY to 45,509 units (82% from retina); TRIESENCE unit demand +136% YoY for 6th consecutive growth quarter.
- Q2 2026 revenue guidance $71M-$81M; full-year 2026 revenue reaffirmed $350M-$365M, Adjusted EBITDA $80M-$100M.

## SEC filing metadata
- accession: 0001493152-26-022227
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2026-05-11T20:10:43+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/0001493152-26-022227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022227
- JSON: https://secwatch.observer/filing/0001493152-26-022227.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022227.txt

## Key facts
- Earnings Releases
  HARROW, INC. reported quarter ended March 31, 2026 results: revenue $44,203,000, net income Net loss $(27,602,000), EPS $(0.74). Guidance reaffirmed.
  - Period: quarter ended March 31, 2026
  - Revenue: $44,203,000
  - Net income: Net loss $(27,602,000)
  - EPS: $(0.74)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues $ 44,203,000 $ 47,831,000 Gross margin 61 % 68 % Net loss (27,602,000 ) (17,780,000 ) Adjusted EBITDA (1) (12,659,000 ) (1,985,000 ) Net loss per share, basic and diluted (0.74 ) (0.50 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/0001493152-26-022227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.